Eli Lilly has entered into a definitive agreement to acquire AtaiBeckley for approximately 2.8 billion dollars to expand its portfolio of treatments for treatment-resistant depression.
Impact
15/100
Current rank score
8.26
Source tier
Tier 2
Category
Funding
Firefly links to the original publisher. The summary above is AI-generated for orientation and may differ from the source. The “current rank score” decays over time so newer significant stories surface first.